← Back to Drugs A–Z

DMT

Group: Psychedelics
Tags: Tryptamines
Nicknames: Dimi, Dimitri, Businessman’s Special, businessman's trip' or 'lunch-break trip, (because of the short duration), the spirit molecule, fantasia
Last reviewed: October 2026

Pharmacology

Dimethyltryptamine (DMT) belongs to a class of chemical compounds called ‘tryptamines’ and acts as an agonist at serotonin receptors, rather than changing how much serotonin the body makes. Its Psychedelic effects are attributed mainly to partial agonism at the 5-HT2A receptor (the traditional psychedelic receptor and the same target as LSD and Psilocybin). DMT also binds to other serotonin receptors and sigma-1 and trace amine receptors with the roles of these still unclear.

DMT is rapidly broken down by monoamine oxidase A (MAO-A), an enzyme found in the gut wall and liver among other places. Swallowed on its own, most of it is destroyed before it reaches the brain. Ayahuasca avoids this by adding Banisteriopsis caapi, which contains harmala alkaloids (harmine, harmaline, tetrahydroharmine) that reversibly inhibit MAO-A. This lets DMT act when swallowed and makes the effects slower, stronger and much longer. The same MAO inhibition is what creates the drug-interaction risks described below. When smoked or injected, DMT bypasses most of this first-pass breakdown, and its action is very short because MAO-A clears it quickly. DMT has low physical toxicity, and there are no well-established deaths from DMT alone. Serious harm is mainly linked to psychological distress, accidents and injuries while impaired, and interactions with other drugs, particularly MAOIs.

Research doses have produced short-lived rises in heart rate and blood pressure and in stress-related hormones (such as cortisol, prolactin and growth hormone).

Unlike LSD and psilocybin, there is little evidence of rapid tolerance with repeated DMT doses in close succession in research settings, though this has been studied in only a small number of people. There is no recognised physical dependence or withdrawal syndrome. Some people use it compulsively or repeatedly, and its very short duration makes repeated use in a session easy.

DMT and the enzyme that can make it (INMT) have been detected in trace amounts in humans and other mammals, so DMT is described as an endogenous compound. Whether the body produces meaningful amounts in the brain, and what, if anything, it does, remains unproven and debated. There is no good evidence that it explains dreaming or near-death experiences.

Keep This Information Independent

Release is a registered charity. We rely on your support to provide expert, non-judgmental legal and harm reduction guidance to thousands of people every year.

Donate to Release